Targeted Nanomedicine for Breast Cancer Therapy

On 3rd June 2026, scientists from the Agharkar Research Institute (ARI), Pune, developed a next-generation nanomedicine platform that selectively targets and silences genes responsible for breast cancer growth, offering a promising approach for precision cancer treatment.

Key Findings

  • Researchers developed a targeted gene-silencing strategy that significantly inhibited tumour growth in breast cancer models.
  • The technology uses biodegradable mesoporous silica nanoparticles to efficiently deliver therapeutic molecules directly to cancer cells.
  • The nanocarrier simultaneously silences two cancer-promoting genes MCL-1 and Survivin.
  • Both genes help tumour cells survive and resist treatment.

How the Technology Works

  • The platform is based on biodegradable mesoporous silica nanoparticles, known for ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy August 2026 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content